Conventional and Non-Conventional Synthesis of Novel (4*E*)-4-((3-(2-(4-fluorophenyl)-4methylthiazol-5-yl)-1-aryl-1*h*-pyrazol-4-yl) methylene)-3-alkyl-1-aryl-1*h*-pyrazol-5(4*h*)-ones

R. K. Jadhav¹, H. N Akolkar² and B. K. Karale^{4*}

¹Assistant Professor, Department of Chemistry, S. M. Joshi College, Hadapsar, Pune- 411028, India. ²Assistant Professor, Department of Chemistry, Radhabai Kale Mahila Mahavidyalaya, Ahmednagar- 414001. ⁴Principal, Chatrapati shivaji college, Satara- 415001.

Abstract : A conventional and non-conventional Knoevenagel condensation of 3-(2-(4-fluorophenyl)-4-methylthiazol-5-yl)-1-aryl-1H-pyrazole-4-carbaldehyde and 3-alkyl-1-aryl-1H-pyrazol-5(4H)-one gave (4E)-4-((3-(2-(4-fluorophenyl)-4-methylthiazol-5-yl)-1-aryl-1H-pyrazol-4-yl)methylene)-3-alkyl-1-aryl-1H-pyrazol-5(4H)-one. The structures of the synthesized compounds were confirmed with the help of spectral techniques.

IndexTerms – conventional, non-conventional, Knoevenagel condensation.

I. INTRODUCTION

Knoevenagel condensation is a reaction in which C-C bond formation takes place and extensively used in synthesis of olefins and pharmacologically active compounds. This condensation is catalysed by different catalysts such as L-tyrosine^[1], [BmIm]OH^[2], lipoprotein lipase^[3], tetrabutylphosphonium prolinate^[4], thermally decomposed mesoporous Ni-Fe hydrotalcite^[5] etc. Fluorinated compounds are of great interest to synthetic and medicinal chemist due to unique physical biological properties imparted by fluorine^[6]. Fluorinated compound possess variety of biological activities like antimicrobial^[7], antibacterial^[8] and anticancer^[9].

Thiazole and its derivative have attracted many researchers due to their pharmacological potentials. Thiazole containing compounds exhibits EP₁ receptor antagonist^[10], VEGF-A inhibitors^[11], cytotoxic^[12], C-aryl glucoside SGLT2 Inhibitor^[13], vascular

adhesion protein-1 (VAP-1) inhibitors^[14] activities. Pyrazolone derivatives possess numerous biological activities like neuraminidase inhibitors^[15], nonallergenic antipyretic analgesics^[16], HIV-1 integrase inhibitors^[17], anti-orthopoxvirus^[18] and anti-bacterial agents^[19].

Now a days microwave & ultrasound irradiations have been extensively used to activate organic reactions. It is a green approach which has many advantages over conventional methods^[20, 21]. Many organic reactions have been carried out in higher yield, shorter reaction time and milder conditions under microwave and ultrasound irradiation^[22-25].

In view of activities associated with fluorinated compounds, thiazole, pyrazolone and use of eco-friendly techniques we describes here the synthesis of (4E)-4-((3-(2-(4-fluorophenyl)-4-methylthiazol-5-yl)-1-aryl-1H-pyrazol-4-yl)methylene)-3-alkyl-1-aryl-1H-pyrazol-5(4H)-one derivatives by conventional and non-conventional methods.

II. Experimental Section

The melting points were determined by open capillary method and are uncorrected. IR spectra were recorded on Shimadzu IR Affinity-1S Fourier transform infrared spectrophotometer. ¹H NMR spectra were recorded on Bruker Avance II 400 MHz NMR spectrometer using TMS as an internal standard and CDCl₃ as a solvent. The mass spectra were recorded on Acquity TQD Waters mass spectrometer. Microwave irradiation was carried out in Raga synthetic microwave system and for ultrasound method Bio techno labs ultrasonicator was used.

(4E) - 4 - ((3 - (2 - (4 - Fluorophenyl) - 4 - methylthiazol - 5 - yl) - 1 - aryl - 1H - pyrazol - 4 - yl) methylene) - 3 - alkyl - 1 - aryl - 1H - pyrazol - 5 (4H) - one, 3a - j

Conventional method: Equimolar amounts of 3-(2-(4-fluorophenyl)-4-methylthiazol-5-yl)-1-aryl-1*H*-pyrazole-4-carbaldehyde**1**(0.002 mol) and pyrazolone**2**(0.002 mol) were taken in glacial acetic acid (15 mL). The reaction mixture was refluxed till completion of reaction (checked by TLC). After completion of reaction, contents were then poured into crushed ice. Solid obtained was filtered, dried and purified by recrystallization from acetic acid to get pure compounds**3a-j**. The physical data of compounds synthesized by above method is given in**Table 1**.

Microwave method: Equimolar amounts of 3-(2-(4-fluorophenyl)-4-methylthiazol-5-yl)-1-aryl-1H-pyrazole-4carbaldehyde 1 (0.002 mol) and pyrazolone 2 (0.002 mol) were taken in glacial acetic acid (15 mL). Contents of flaskwere subjected for microwave irradiation at 350W for time as shown in table, till completion of reaction (checked by

TLC). After completion of reaction, contents were poured into crushed ice. Solid obtained was filtered, dried and purified by recrystallization from acetic acid to get pure compounds **3a-j**. Formations of products were also confirmed by M. P., mixed M. P. and TLC. The physical data of compounds synthesized by above method is given in Table 1.

Ultrasound Method: Equimolar amounts of 3-(2-(4-fluorophenyl)-4-methylthiazol-5-yl)-1-aryl-1H-pyrazole-4carbaldehyde 1 (0.002 mol) and pyrazolone 2 (0.002 mol) were taken in glacial acetic acid (15 mL). Contents of flask were subjected for ultrasound irradiation for time as shown in table, till completion of reaction (checked by TLC). After completion of reaction, contents were poured into crushed ice. Solid obtained was filtered, dried and purified by recrystallization from acetic acid to get pure compounds 3a-j. Formations of products were also confirmed by M. P., mixed M. P. and TLC. The physical data of compounds synthesized by above method is given in Table 1.

3a: IR: 3138, 1693, 1597, 1512, 1217 cm⁻¹; ¹HNMR (CDCl₃): δ 2.30 (s, 3H), 2.59 (s, 3H), 7.16-8.01 (m, 14H), 10.28 (s, 1H); Mass: *m/z* 537 (M+); Elem. anal. calcd. for C₃₀H₂₁F₂N₅OS: C, 67.03; H, 3.94; N, 13.03 %. Found: C, 67.07; H. 3.98; N. 13.08 %.

3b: IR: 3135, 1690, 1594, 1516, 1214 cm⁻¹; ¹HNMR (CDCl₃): δ 2.31 (s, 3H), 2.62 (s, 3H), 7.16-8.00 (m, 13H), 10.28 (s, 1H); Mass: m/z 555 (M+); Elem. anal. calcd. for $C_{30}H_{20}F_3N_5OS$: C, 64.86; H, 3.63; N, 12.61 %. Found: C, 64.91; H, 3.67; N, 12.65 %.

3c: IR: 3136, 1692, 1593, 1514, 1213 cm⁻¹; ¹HNMR (CDCl₃): δ 2.30 (s, 3H), 2.58 (s, 3H), 7.15-8.09 (m, 13H), 10.21 (s, 1H); Mass: m/z 571 (M+); Elem. anal. calcd. for C₃₀H₂₀ClF₂N₅OS: C, 62.99; H, 3.52; N, 12.24 %. Found: C, 63.03; H, 3.57; N, 12.28 %.

3d: IR: 3138, 1694, 1592, 1516, 1211 cm⁻¹; ¹HNMR (CDCl₃): δ 2.58 (s, 3H), 7.16-8.01 (m, 14H), 10.21 (s, 1H); Mass: *m*/*z* 591 (M+); Elem. anal. calcd. for C₃₀H₁₈F₅N₅OS: C, 60.91; H, 3.07; N, 11.84 %. Found: C, 60.95; H, 3.12; N, 11.89 %.

3e: IR: 3140, 1690, 1591, 1514, 1213 cm⁻¹; ¹HNMR (CDCl₃): δ 1.04 (t, 3H), 1.80 (sextet, 2H), 2.58-2.62 (m, 5H), 7.15-8.01 (m, 14H), 10.23 (s, 1H); Mass: m/z 565 (M+); Elem. anal. calcd. for C₃₂H₂₅F₂N₅OS: C, 67.95; H, 4.45; N, 12.38 %. Found: C, 67.99; H, 4.49; N, 12.42 %.

3f: IR: 3139, 1694, 1598, 1515, 1211 cm⁻¹; ¹HNMR (CDCl₃): δ 2.31 (s, 3H), 2.58 (s, 3H), 7.15-8.01 (m, 15H), 10.29 (s, 1H); Mass: m/z 519 (M+); Elem. anal. calcd. for C₃₀H₂₂FN₅OS: C, 69.35; H, 4.27; N, 13.48 %. Found: C, 69.39; H, 4.31; N, 13.52 %.

3g: : IR: 3135, 1690, 1594, 1516, 1214 cm⁻¹; ¹HNMR (CDCl₃): δ 2.30 (s, 3H), 2.61 (s, 3H), 7.15-8.00 (m, 14H), 10.27 (s, 1H); Mass: m/z 537 (M+); Elem. anal. calcd. for $C_{30}H_{21}F_2N_5OS$: C, 67.03; H, 3.94; N, 13.03 %. Found: C, 67.07; H, 3.98; N, 13.08 %.

3h: IR: 3138, 1690, 1593, 1513, 1212 cm⁻¹; ¹HNMR (CDCl₃): δ 2.31 (s, 3H), 2.58 (s, 3H), 7.15-8.08 (m, 14H), 10.22 (s, 1H); Mass: m/z 553 (M+); Elem. anal. calcd. for C₃₀H₂₁ClFN₅OS: C, 65.04; H, 3.82; N, 12.64 %. Found: C, 65.08; H, 3.86; N, 12.68 %.


3i: IR: 3139, 1694, 1591, 1517, 1212 cm⁻¹; ¹HNMR (CDCl₃): δ 2.59 (s, 3H), 7.15-8.01 (m, 15H), 10.20 (s, 1H); Mass: *m*/*z* 573 (M+); Elem. anal. calcd. for C₃₀H₁₉F₄N₅OS: C, 62.82; H, 3.34; N, 12.21 %. Found: C, 62.86; H, 3.38; N, 12.25 %

3j: IR: 3142, 1691, 1592, 1515, 1213 cm⁻¹; ¹HNMR (CDCl₃): δ 1.05(t, 3H), 1.81 (sextet, 2H), 2.57-2.61 (m, 5H), 7.16-8.07 (m, 15H), 10.24 (s, 1H); Mass: m/z 547 (M+); Elem. anal. calcd. for C₃₂H₂₆FN₅OS: C, 70.18; H, 4.79; N, 12.79 %. Found: C, 70.22; H, 4.83; N, 12.83 %.

Compd	R	R ₁	R ₂	M.P. (⁰ C)	Conventional Method		Microwave Method		Ultrasound Method	
					Time (Min)	Yield (%)	Time (Min)	Yield (%)	Time (Min)	Yield (%)
3a	CH ₃	Н	F	220	58	74	5	80	21	88
3b	CH_3	4-F	F	276	60	76	7	79	23	87
3c	CH_3	3-Cl	F	280	60	71	7.5	81	20	90
3d	CF_3	Н	F	256	51	70	8	78	21	92
3e	C_3H_7	Н	F	160	67	68	7	80	22	91
3f	CH_3	Н	Н	230	63	73	6.5	78	24	88
3g	CH_3	4-F	Н	278	60	74	7.5	80	21	87
3h	CH_3	3-Cl	Н	240	68	76	8	82	23	90
3i	CF_3	Н	Н	228	54	69	6	77	20	89
3ј	C_3H_7	Н	Н	180	55	72	5.5	80	26	90

Table 1: Characterization data of the synthesized compounds

Scheme-1



References

- [1] Thirupathi, G.; Venkatanarayana, M.; Dubey, P. K.; Bharathi Kumari, Y. 2012, L-tyrosine catalyzed knoevenagel condensation: facile synthesis of cyanoacrylonitriles cyanoacrylates and cyanoacrylamides in solvent free condition under grindstone method, Der Pharma Chem., 4, 1897-1901.
- [2] Ranu, B. C.; Jana, R. 2006, Ionic Liquid as Catalyst and Reaction Medium A Simple, Efficient and Green Procedure for Knoevenagel Condensation of Aliphatic and Aromatic Carbonyl Compounds Using a Task-Specific Basic Ionic Liquid, Eur. J. Org. Chem., 3767-3770.
- [3] Mostafa, M. G.; Mahmoud, S. B.; Mansour, S. A. 2014, Novel thiophene derivatives with sulfonamide, isoxazole, benzothiazole, quinoline and anthracene moieties as potential anticancer agents, ActaPharma., 64, 419-431.
- [4] Ouyang, F.; Zhou, Y.; Li, Z.; Hu, N.; Tao, D. 2014, Tetrabutylphosphonium amino acid ionic liquids as efficient catalysts for solvent free knoevenagel condensation reactions, Korean J. Chem. Eng., 31(8), 1377-1383.
- [5] Dumbre, D. K.; Mozammel, T.; Selvakannan, P. R.; Abdul Hamid, S. B.; Choudhary, V. R.; Bhargava, S. K. 2015, Thermally decomposed mesoporous nickel iron hydrotalcite: An active solid-base catalyst for solvent free knoevenagel condensation, J. Coll. Int. Sci., 441, 52-58.
- [6] Hudlicky, M. 1992, Chemistry of Organic Fluorine Compounds, Ellis Horwood Ltd., Chichester.
- [7] Shelke, S. N.; Dalvi, N. R.; Kale, S. B.; More, M. S.; Gill C. H.; Karale, B. K. 2007, Synthesis of pyrazolone derivatives and their antimicrobial activity, *Indian J. Chem.*, 46B, 1174-1178.
- [8] Patel, V. M.; Desai, K. R. 2005, Microwave-induced synthesis of fluorine containing 1,5-disubstituted hydantoins and thiohydantoins and their antibacterial activity, Indian J. Chem., 44B, 1084-1087.
- [9] Hammam, A. E. G.; EI-Salam, O. I. A.; Mohamed A. M.; Hafez, N. A. 2005, Novel fluoro substituted benzo[b]pyran with anti lung cancer activity, Indian J. Chem., 44B, 1887-1893.
- [10] Atobe, M.; Naganuma, K.; Kawanishi, M.; Morimoto, A.; Kasahara, K.; Ohashi, S.; Suzuki, H.; Hayashi and Miyoshi, S.
 2013, SAR-based optimization of 2-(1H-pyrazol-1-yl)-thiazole derivatives as highly potent EP1 receptor antagonists.
 Bioorg. Med. Chem. Lett., 23, 6569-6576.
- [11] T. Prashanth, P. Thirusangu, T.; Vijay Avin, B. R.; Ranganatha, V. L.; Prabhakar B. T.; Khanum, S. A. Synthesis and evaluation of novel benzophenone-thiazole derivatives as potent VEGF-A inhibitors. Eur. J. Med. Chem., 2014, 87, 274-283.
- [12] Patterson, A. W.; Peltier, H. M.; Ellman, J. A. Expedient Synthesis of *N*-Methyl Tubulysin Analogues with High Cytotoxicity, *J.* Org. Chem., 2008, *73*, 4362–4369.
- [13] Song, K.; Lee, S. H.; Kim, M. J.; Seo, H. J.; Lee, J.; Lee, S.; Jung, M. E.; Son, E.; Lee, M. W.; Kim, J.; Lee, J. 2011, Synthesis and SAR of Thiazolylmethylphenyl Glucoside as Novel C-Aryl Glucoside SGLT2 Inhibitors, ACS Med. Chem. Lett., 2, 182-187.

© 2019 JETIR June 2019, Volume 6, Issue 6

- [14] Inoue, T.; Morita, M.; Tojo, T.; Yoshihara, K.; Nagashima, A.; Moritomo, A.; Ohkubo, M.; Miyake, H. 2013, Synthesis and SAR study of new thiazole derivatives as vascular adhesion protein-1 (VAP-1) inhibitors for the treatment of diabetic macular edema. *Bioorg.* Med. Chem., 21, 1219-1233.
- [15] Kumar, V.; Chang, C.; Tan, K.; Jung, Y.; Chen, S.; Cheng Y. E.; Liang, P. Identification, Synthesis, and Evaluation of New Neuraminidase Inhibitors, Org. Lett., 2014, 16, 5060-5063.
- [16] Uramaru, N.; Shigematsu, H.; Toda, A.; Eyanagi, R.; Kitamura S.; Ohta, S. 2010, Design, synthesis, and pharmacological activity of nonallergenic pyrazolone-type antipyretic analgesics. J. Med. Chem., 53, 8727-8733.
- [17] Hadi, V.; Koh, Y.; Sanchez, T. W.; Barrios, D.; Neamati, N.; Jung, K. W. 2010, Development of the next generation of HIV-1 integrase inhibitors: pyrazolone as a novel inhibitor scaffold. Bioorg. Med. Chem. Lett., 20, 6854-6857.
- [18] Fan, X.; Zhang, X.; Zhou, L.; Keith, K. A.E.; Kern, R.; Torrence, P. F. 2006, Pyrimidine-pyrazolone nucleoside chimera with potent in vitro anti-orthopoxvirus activity, Bioorg. Med. Chem. Lett., 16, 3224-3228.
- [19] Indrasena, A.; Riyaz, Sd.; Mallipeddi, P. L.; Padmaja, P.; Sridhar B.; Dubey, P. K. 2014, Design, synthesis, and biological evaluation of indolylidinepyrazolones as potential anti-bacterial agents, Tet. Lett., 55, 5014-5018.
- [20] Varma, R. S. 1999, Solvent-free organic syntheses using supported reagents and microwave irradiation, Green Chem., 1, 43-55.
- [21] Chen, D.; Sharma, S. K.; Mudhoo, A. 2012. Handbook on Applications of Ultrasound: Sonochemistry for Sustainability, Eds, CRC Press: Boca Raton.
- [22] Zang, H.; Y. Zhang, Y.; Zang, B. W. Cheng, 2010, An efficient ultrasound-promoted method for the one-pot synthesis of 7,10,11,12-tetrahydrobenzo[c]acridin-8(9H)-one derivatives. Ultrason. Sonochem., 17, 495-499.
- [23] H. Zang, Q. Su, Y. Mo, B. W. Cheng and S. Jun, 2010, Ionic liquid [EMIM]OAc under ultrasonic irradiation towards the first synthesis of trisubstituted imidazoles.Ultrason. Sonochem, 17(5), 749-751.
- [24] Gupta, M.; Wakhloo, B. P. 2007, Tetrabutylammonium Bromide Mediated Knoevenagel Condensation in Water: Synthesis of Cinnamic Acids, Arkivoc, i, 94-98.
- [25] Surati, M. A.; Jauhari S.; Desai, K. R. A brief review: Microwave.